Gordon is an Associate Partner in the Competitive Strategy practice at Prescient. He leads some of the largest and most complex competitive strategy engagements guiding and mentoring teams into becoming oncology SMEs, helping them see early patterns in the oncology space.
Gordon began his career at DaVinci Healthcare Partners (now part of Oracle) where be became expert on oncology standards or care and drug development strategy as well as forecasting and epidemiology expertise [there may be a better way to phrase this]. Additionally, spent 3 years in oncology pricing and access first at Kantar Health and later PricePpective (now part of Icon).
His therapeutic experience spans oncology indications not just focusing on the big 3 solid tumors (NSCLC, BC, and CRC) but also including HNSCC, melanoma, gastric, PDAC, HNSCC, CSCC, BTC, ovarian, endometrial, and GBM, as well as all hem onc indications (CML, CLL, DLBCL, MCL, ET, PV, MF, and T cell lymphoma).
Gordon has led major CI programs for large pharma and small biotech for early commercial and in-line oncology assets. He has also led quantative demand and qualitative market research engagements specializing in KOL discussions, working with a range of clients including market access clients with drug pricing or NPP clients with opportunity assessments.
Gordon prides himself on making the complex simple for clinical development, commercial, and medical affairs clients. He says that ‘everything reminds me of something’ over his 20+ years of experience in the oncology space.
